SHANGHAI, Jan. 7, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development services company, with operations in China and the United States, today announced that it will present at the 31th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 8:30 a.m. Pacific Standard Time and updated its 2012 financial guidance. Based on preliminary, unaudited results, WuXi expects to achieve total revenues of approximately $500 million and to meet the remainder of the 2012 financial guidance found in its third-quarter 2012 earnings release.
WuXi plans to report its audited fourth-quarter and full-year 2012 financial results and to provide 2013 financial guidance in March 2013.
For more information, please contact:
Ronald Aldridge (for investors)
Director, Investor Relations
Aaron Shi (for the media)
Assistant Director, Corporate Communications
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including those with respect to our financial guidance for full-year 2012 and prospects generally, are based on our preliminary unaudited results and are subject to the completion of our 2012 audit. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. All projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law. Such information speaks only as of the date of this release.
SOURCE WuXi PharmaTech